Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer

British Journal of Cancer

Volumn 105, Issue 8, 2011, Pages 1144-1150

  Lee, C K ^a   Simes, R J ^a   Brown, C ^a   Lord, S ^a   Wagner, U ^b   Plante, M ^c   Vergote, I ^d   Pisano, C ^e   Parma, G ^f   Burges, A ^g   Bourgeois, H ^h   Hogberg T ⁱ   Bentley, J ^j   Angleitner Boubenizek, L ^k   Ferrero, A ^l   Richter, B ^m   Hirte, H ⁿ   Gebski, V ^a   Pfisterer, J ^o   Pujade Lauraine, E ^p   Friedlander, M ^q   more..

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY HOSPITAL MARBURG   (Germany)

^c LAVAL UNIVERSITY   (Canada)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^g LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^h CENTRE JEAN BERNARD   (France)

ⁱ LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^j DALHOUSIE UNIVERSITY   (Canada)

^k BHS Linz   (Austria)

^l MAURIZIANO HOSPITAL   (Italy)

^m DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

ⁿ JURAVINSKI CANCER CENTRE   (Canada)

^o Staedt Klinikum Solingen   (Germany)

^p UNIVERSITÉ PARIS DESCARTES   (France)

^q PRINCE OF WALES HOSPITAL   (Australia)

more..

Author keywords

nomogram; platinum sensitivity; prognosis; progression free survival; recurrent ovarian cancer

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; DOXORUBICIN; GEMCITABINE; PACLITAXEL; PLATINUM;

ADULT; ARTICLE; CALIBRATION; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CONTROLLED STUDY; FEMALE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; METASTASIS; MULTIPLE CYCLE TREATMENT; NOMOGRAM; OVARY CANCER; PATIENT SELECTION; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; RECURRENT CANCER; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARBOPLATIN; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS;

EID: 80053999734     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.364     Document Type: Article

References (33)

1. Bishara S, Griffin M, Cargill A, Bali A, Gore ME, Kaye SB, Shepherd JH, Van Trappen PO (2008) Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer. Eur J Obstet Gynecol Reprod Biol 138: 71-75 (Pubitemid 351608106)
2. Blackledge G, Lawton F, Redman C, Kelly K (1989) Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials. Br J Cancer 59: 650-653 (Pubitemid 19111764)
3. Cantu MG, Buda A, Parma G, Rossi R, Floriani I, Bonazzi C, Dell'Anna T, Torri V, Colombo N (2002) Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 20: 1232-1237 (Pubitemid 34177429)
4. Cho H, Hur H, Kim S, Kim S, Kim J, Kim Y, Lee K (2009) Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 58: 15-23
5. Cox D (1972) Regression models and life-tables. J R Stat Soc B 34: 187-220
6. Du Bois A, Luck H-J, Meier W, Adams H-P, Mobus V, Costa S, Bauknecht T, Richter B, Warm M, Schroder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J (2003) A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95: 1320-1329
7. Eisenhauer E, Vermorken J, van Glabbeke M (1997) Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients. Ann Oncol 8: 963-968 (Pubitemid 27475726)
8. Ferrandina G, Ludovisi M, Corrado G, Carone V, Petrillo M, Scambia G (2008) Prognostic role of Ca125 response criteria and RECIST criteria: analysis of results from the MITO-3 phase III trial of gemcitabine versus pegylated liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol 109: 187-193
9. Ferrero J-M, Weber B, Geay J-F, Lepille D, Orfeuvre H, Combe M, Mayer F, Leduc B, Bourgeois H, Paraiso D, Pujade-Lauraine E (2007) Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial. Ann Oncol 18: 263-268 (Pubitemid 46323091)
10. Gordon AN, Tonda M, Sun S, Rackoff W (2004) Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 95: 1-8 (Pubitemid 39286270)
11. Gore M, Fryatt I, Wiltshaw E, Dawson T (1990) Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 36: 207-211 (Pubitemid 20061287)
12. Gronlund B, Hogdall C, Hilden J, Engelholm S, Hogdall E, Hansen H (2004) Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma? J Clin Oncol 22: 4051-4058 (Pubitemid 41199651)
13. Hagerty RG, Butow PN, Ellis PA, Lobb EA, Pendlebury S, Leighl N, Goldstein D, Lo SK, Tattersall MHN (2004) Cancer patient preferences for communication of prognosis in the metastatic setting. J Clin Oncol 22: 1721-1730 (Pubitemid 41079812)
14. Harrell Jr F, Lee K, Mark D (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stats Med 15: 361-387 (Pubitemid 26072233)
15. Hopper K, Kasales C, Van Slyke M, Schwartz T, TenHave T, Jozefiak J (1996) Analysis of interobserver and intraobserver variability in CT tumor measurements. Am J Roentgenol 167: 851-854 (Pubitemid 26322230)
16. Hoskin P, O'Reilly S, Swenerton K (1991) The 'failure free interval' defines the likelihood of resistance to carboplatin in patients with advanced epithelial ovarian cancer previously treated with cisplatin: relevance to therapy and new drug testing. Int J Gynecol Cancer 1: 205-208
17. ICON and AGO collaborators (2003) Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361: 2099-2106
18. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA: Cancer J Clin 61: 69-90
19. Kiely BE, Soon YY, Tattersall MHN, Stockler MR (2011) How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials. J Clin Oncol 29: 456-463
20. Mackillop WJ, Quirt CF (1997) Measuring the accuracy of prognostic judgments in oncology. J Clin Epidemiol 50: 21-29 (Pubitemid 27089204)
21. Markman M, Rothman R, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Lewis Jr J (1991) Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9: 389-393
22. May S, Hosmer DW, Balakrishnan N, Rao CR (2003) Hosmer and lemeshow type goodness-of-fit statistics for the Cox proportional hazards model. In Handbook of Statistics, Vol. 23, pp 383-394. Elsevier: Amsterdam, North-Holland
23. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334: 1-6 (Pubitemid 26012496)
24. McMillan DC (2009) Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 12: 223-226
25. Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Lisyanskaya AS, Makhson AN, Rolski J, Gorbounova VA, Ghatage P, Bidzinski M, Shen K, Ngan HY-S, Vergote IB, Nam J-H, Park YC, Lebedinsky CA, Poveda AM (2010) Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol 28: 3107-3114
26. Ozols R, Bundy B, Greer B, Fowler J, Clarke-Pearson D, Burger R, Mannel R, DeGeest K, Hartenbach E, Baergen R (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 21: 3194-3200 (Pubitemid 46606249)
27. Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, Wagner U, Stahle A, Stuart G, Kimmig R, Olbricht S, Le T, Emerich J, Kuhn W, Bentley J, Jackisch C, Luck H-J, Rochon J, Zimmermann AH, Eisenhauer E (2006) Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24: 4699-4707 (Pubitemid 46630933)
28. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, Grimshaw R, Atkinson RJ, Swenerton KD, Trope C, Nardi M, Kaern J, Tumolo S, Timmers P, Roy JA, Lhoas F, Lindvall B, Bacon M, Birt A, Andersen JE, Zee B, Paul J, Baron B, Pecorelli S (2000) Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin- cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92: 699-708 (Pubitemid 30365530)
29. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A, Sehouli J, Lortholary A, Kristensen G, Jackisch C, Joly F, Brown C, Le Fur N, du Bois A (2010) Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 28: 3323-3329
30. Schultheis A, Lurje G, Rhodes K, Zhang W, Yang D, Garcia A, Morgan R, Gandara D, Scudder S, Oza A, Hirte H, Fleming G, Roman L, Lenz H (2008) Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res 14: 7554-7563
31. Sharma R, Hook J, Kumar M, Gabra H (2008) Evaluation of an inflammation-based prognostic score in patients with advanced ovarian cancer. Eur J Cancer 44: 251-256
32. Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom A, Christian M, Gwyther S (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216 (Pubitemid 30099779)
33. Thigpen J, Blessing J, Ball H, Hummel S, Barrett R (1994) Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. J Clin Oncol 12: 1748-1753 (Pubitemid 24349373)